Farhad Ravandi-Kashani, MD
M.D. Anderson Cancer Center · MD Anderson · UT MD Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
17
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in childhood acute lymphoblastic leukemia
0
PubMed author-name match
Trials
Studies that name Farhad Ravandi-Kashani, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:21 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06021600 · A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous CladribineM.D. Anderson Cancer Center · terminated · Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia · principal investigator
- Ph2NCT04746235 · Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid LeukemiaM.D. Anderson Cancer Center · active not recruiting · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1NCT03048344 · A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological DisordersOrsenix LLC · completed · Advanced Hematological Disorders · principal investigator
- Ph1/Ph2NCT02464657 · Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome · principal investigator
- Ph2NCT02196857 · Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD MutationM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT02089230 · MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard TherapyM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph1NCT01891981 · Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph2NCT01786343 · Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1/Ph2NCT01254890 · Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic SyndromeM.D. Anderson Cancer Center · completed · Leukemia · principal investigator
- Ph1NCT00981240 · Dose Escalation, Safety and Pharmacokinetic Study of SAR103168 in Patients Refractory/ Relapsed Acute Leukemias or High-risk Myelodysplastic SyndromesSanofi · completed · Acute Myelogenous Leukemia · principal investigator
- Ph1NCT00642031 · Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic MalignanciesPrescient Therapeutics, Ltd. · completed · Hematologic Malignancies, Leukemia · principal investigator
- Ph1/Ph2NCT00542971 · Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)M.D. Anderson Cancer Center · completed · AML, Acute Myeloid Leukemia, Myelodysplastic Disorders · principal investigator
- Ph2NCT00453193 · Alemtuzumab and Pentostatin In T-cell NeoplasmsM.D. Anderson Cancer Center · terminated · Lymphoma, Leukemia · principal investigator
- Ph2NCT00422591 · Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Leukemia, Acute Myeloid Leukemia, AML · principal investigator
- Ph2NCT00413166 · All-trans Retinoic Acid, and Arsenic +/- IdarubicinM.D. Anderson Cancer Center · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph2/Ph3NCT00398983 · Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)M.D. Anderson Cancer Center · completed · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT00390793 · Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.M.D. Anderson Cancer Center · completed · Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.